louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06229262: Immune and Cognitive Benefits of Mango Intake in Young Adults
Official title: Immune and Cognitive Benefits of Mango Intake in Young Adults: A Randomized Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cognition
Immunity
Keywords: Mango
Immunity
cognition
Lead sponsor: Loma Linda University
Sponsor class: OTHER
Collaborators: name: National Mango Board
First posted: 2024-01-29
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: this will be a12 week, parallel study , free living with college going young adults aged 18-30 years
Primary purpose: PREVENTION

Brief summary: The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30 years

Detailed description: The main objectives of our proposed study are to determine the effects of mango consumption on immune and cognitive functions in free-living college going young adults aged 18-30. To accomplish these objectives, a randomized controlled, parallel design study is proposed with two groups consuming their habitual diet, but with one (Mango group) receiving 1.5 servings of mango/day and the other (Control group) abstaining from eating any mango for the duration of the study.

Eligibility criteria: Inclusion Criteria:

* Male and female college students aged 18-30 years

Exclusion Criteria:

* known intolerance or allergy to mangos
* regular intake of mangos and/or fruits of a similar nutritional content such as peach, nectarine, papaya, apricot and cantaloupe
* using cognition and/or immune-boosting supplements or vitamins
* recent exposure to antibiotics and corticoids
* uncontrolled chronic diseases and mental illnesses, clinical depression, and immunocompromised state

Primary outcomes:
measure: Changes in lymphocyte populations
timeFrame: baseline to 12 weeks
measure: Changes in Lymphocyte activity
timeFrame: baseline to 12 weeks
measure: Changes in cytokine production
timeFrame: baseline to 12 weeks
measure: Changes in serum inflammatory cytokine concentration
timeFrame: baseline to 12 weeks
measure: changes from baseline in global cognitive composite score
timeFrame: baseline to 12 weeks
measure: Change in serum brain-derived neurotrophic factor (pg/mL)
timeFrame: baseline to 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University School of Public Health
state: California
Study officials:
affiliation: Loma Linda University
name: Sujatha Rajaram, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02443662: Colloid Osmotic Pressure in Patients With Fontan Circulation
Official title: Interstitial Colloid Osmotic Pressure in Children With Fontan Circulation After Fontan Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Defects, Congenital
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: University of Bergen
First posted: 2015-05-14
Enrollment: 12
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children who will have a cathererization during their routine check up 10 years after completion of Fontan surgery.

Brief summary: Children born with univentricular heart will go through step surgery and end up with a Fontan circulation. A circulation with cause problems with body fluid balance.This project will evaluate changes in interstitial colloid osmotic pressure in patients 10 year after completion of a three step Fontan surgery. This project will evaluate whether increased micro vascular leakage and change in interstitial colloid osmotic pressure are present in patients after ten years with a Fontan circulation.


Eligibility criteria: Inclusion Criteria:

* Fontan circulation after completed Fontan surgery.
* Anesthesia during catheterization.

Exclusion Criteria:

* No consent

Primary outcomes:
measure: Interstitial colloid osmotic pressure
timeFrame: Ten years after completed Fontan surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Oslo University Hospital
name: Marianne Indrebø, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04748562: Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies
Official title: Vaginal Progesterone 400mg v.s 200mg for Prevention of Preterm Labor in Twin Pregnancies: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Twin Pregnancy With Antenatal Problem
Keywords: Progesterone
Twin pregnancy
Preterm labor
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-02-10
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial
Primary purpose: PREVENTION

Brief summary: It is already known that the risk of preterm labor in twin pregnancy before 37 week is 8-9 fold higher compared to singletons, and progesterone supplementation can decrease the incidence of preterm labor in singleton pregnancy.

There were studies that used 200mg vaginal progesterone with no effect on the result So this study aims To examine the effect of prophylactic vaginal progesterone 400mg v.s 200mg for prevention of preterm birth in twin pregnancies


Eligibility criteria: Inclusion Criteria:

1. Primigravidae
2. Twin pregnancies at gestational age 14 week.
3. Cervical length more than 2 cm (because if 2cm or less they will undergo cervical cerclage.)

Exclusion Criteria:

* Polyhydramnios
* Anemia
* Twins with congenital malformation
* Twin to twin transfusion
* Medical diseases as diabetes mellitus, hypertension and systemic lupus erythematosis
* Previous cervical surgery
* High order pregnancy (triples or more)

Primary outcomes:
measure: Preterm labor
timeFrame: Before 37 weeks gestation
Secondary outcomes:
measure: Cervical length changes
timeFrame: Between 14 weeks and 22 weeks gestation
measure: Neonatal ICU admission
timeFrame: The first 28 days after delivery
measure: Neonatal mechanical ventilation
timeFrame: The first 28 days after delivery
measure: Progesterone side effects
timeFrame: During one year which is the period from the start of the study till its end
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Maternity hospital
Study officials:
References:
Clinical trial NCT04618562: Revival Active Program for Adolescents With Depression
Official title: Impact of Revival Active Program on Adolescents With Depression: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depression
Keywords: Adolescent
Revival Active Program
Lead sponsor: Revival Active
Sponsor class: OTHER
Collaborators: name: L.E.A.D
name: NMP Medical Research Institute
First posted: 2020-11-06
Enrollment: 68
Sex: ALL
Minimum age (years): 10
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Active play and sports has shown to be effective intervention in managing depression. Extending the support with Mind body therapy, Revival Active Program was designed as an early intervention for adolescents.

To measure the efficacy and feasibility of the community based revival active play intervention for adolescent depression, present pilot study was undertaken.


Eligibility criteria: Inclusion Criteria:

* Children diagnosed with depression as per the DSM IV-TR criteria
* Parents willing to give written informed consent

Exclusion Criteria:

* Physical limitation for active sports
* Co-morbid mental health diagnosis
* high risk of self harm/ suicide
* history of self harm or harming someone else

Primary outcomes:
measure: Depression
timeFrame: Changes from baseline depression at 8-week
Secondary outcomes:
measure: Self-Efficacy for Children
timeFrame: Changes from baseline self -efficacy at 8-week
Other outcomes:
Locations:
city: Jaipur
country: India
facility: Gyansanjeevani
state: Rajasthan
Study officials:
affiliation: Revival Active Limited
name: Rakesh Patel
role: STUDY_DIRECTOR
affiliation: Revival Active Limited
name: Tejal Patel
role: STUDY_DIRECTOR
affiliation: L.E.A.D
name: Sadhana Sharma
role: STUDY_CHAIR
affiliation: NMP Medical Research Institute, India
name: Sahil Signal
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00262262: The Effect of Levetiracetam on the Postmastectomy Pain Syndrome
Official title: The Effect of Levetiracetam on the Postmastectomy Pain Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2005-12-06
Enrollment: 25
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study is determine whether or not the antiepileptic drug Levetiracetam is an effective treatment of the postmastectomy pain syndrome.

Detailed description: This study is a randomised, placebocontrolled, doubleblind study on the effect of the antiepileptic drug, levetiracetam, in patients suffering from PMPS. The treatment periods are 1 month each and the periods are separated by a 1-week washout period. The daily dose of levetiracetam is increased over a 2-week period to 3.000 mg/day. The primary effect variable is pain relief by the use of numeric rating scale. Secondary parameters are daily registration of pain performed by the patients during the treatment periods and the amount of escape medicine used (paracetamol and tramadol). Sensory testing is performed at baseline and after each treatment period.

Eligibility criteria: Inclusion Criteria:

* Symptoms characteristic for postmastectomy pain syndrome with a duration of more than 3 months and at least 6 months after the operation.
* Neuropathic pain diagnose confirmed by abnormities in the neurological investigation and/or psychophysical sensory testing
* Average (1 week) pain score minimum 4 on a 11 points numerical rating scale for total pain.
* Pain present minimum 4 out of 7 days.
* Fertile women must use anticonception.

Exclusion Criteria:

* Verified og suspected other reason than mastectomy/lumpectomy for the pain.
* Known allergic effects to levetiracetam.
* Known sideeffects to treatment with levetiracetam.
* Pregnancy or breast-feeding.
* Severe disease (terminal cancer, heart failure, kidney insufficiency, severe respiratory problems)
* Compliance problems

Primary outcomes:
measure: Pain relief
timeFrame: After 1 month treatment
Secondary outcomes:
measure: Pain intensity measured daily on numeric rating scales
timeFrame: During treatment periods
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Department of neurology, Odense Universityhospital
state: Fyn
Study officials:
affiliation: Odense University Hospital
name: Ole J Vilholm, MD
role: STUDY_DIRECTOR
affiliation: Odense University Hospital
name: Søren H Sindrup, Professor MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of oncology, Odense University Hospital, Denmark
name: Søren Cold, MD
role: STUDY_CHAIR
affiliation: Department of surgery, Odense University Hospital, Denmark
name: Lars Rasmussen, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01168362: Korea Atherosclerosis Study-3
Official title: Evaluation of Coronary Artery Disease With Multidetector-Row Cardiac Computed Tomography in Positive Cardiovascular Risk or Not
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Diseases
Cardiovascular Mortality
All-cause Mortality
Keywords: coronary artery disease
cardiovascular risk
pericardial fat
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2010-07-23
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: positive cardiovascular risks or not

Brief summary: Multidetector-row Computed Tomography (CT) has been introduced for use in the diagnosis of coronary heart disease. The investigators aimed to characterize coronary artery disease in subjects with cardiovascular risk or not, and in particular plaque natures depending on different status of cardiovascular risk. Especially,the investigators will evaluate the relationships between the pericardial fat and severity of stenosis as well as plaque characteristics using logistic regression models.


Eligibility criteria: Inclusion Criteria:

* Korean capable of Multidetector-Row Cardiac Computed Tomography (MDCT)

Exclusion Criteria:

* malignancy
* infection
* shock

Primary outcomes:
measure: Presence of coronary artery disease
timeFrame: 5 years
Secondary outcomes:
measure: Mortality
timeFrame: 5 years
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Soo Lim, MD,PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04056962: Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Official title: Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma：a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2019-08-14
Enrollment: 50
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Detailed description: Kaposiform hemangioendothelioma (KHE) and tufted angiomas (TA) are rare vascular tumors, which are apparent predominantly in infancy or early childhood. Currently, no standard treatment regimens exist for KHE/TA. The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Eligibility criteria: Inclusion Criteria:

* Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)

Exclusion Criteria:

* Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)

Primary outcomes:
measure: reduction in the size of the lesion
timeFrame: 2.5 years
Secondary outcomes:
measure: Rate of Adverse events
timeFrame: 2.5 years
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
state: Sichuan
Study officials:
affiliation: West China Hospital
name: Yi Ji
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02156362: Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Official title: Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Thyroid Cancer
Keywords: Thyroid carcinoma
predictive factors
refractory
Differentiated
follicular origin
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2014-06-05
Enrollment: 643
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.

The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.


Eligibility criteria: Inclusion Criteria:

* Man or woman ≥ 18 years.
* Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
* TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
* Patient after post operative radioiodine therapy.

Exclusion Criteria:

* Patient who can not be followed during the protocol.
* Patient who does not consent.

Primary outcomes:
measure: Rate of Thyroid cancer evolving to refractory stage
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bron cedex
country: France
facility: Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel
Study officials:
affiliation: Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex
name: Claire BOURNAUD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04396262: Effect of Processed Blueberry on Blood Glucose and Antioxidant Status in Human Adults
Official title: Effect of Hydro-Thermodynamic (HTD) Processed Blueberries on Postprandial Blood Glucose Control and Antioxidant Status in Human Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Glucose
Keywords: Blueberry
Blood Glucose
Antioxidants
Hydro-Thermodynamic Processing
Beverages
Lead sponsor: Mount Saint Vincent University
Sponsor class: OTHER
First posted: 2020-05-20
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Canada's Food Guide (2007) recommended 7-10 servings of fruits and vegetables per day for a normal adult population. Although fruit juice (125 ml) is considered as one serving of fruits, the consumption of some fruit juices may be limited due to their high amount of sugar. The consumption of sugary drinks can lead to a rapid rise in postprandial glycaemia. Wild blueberries, due to their high level of anthocyanins, may provide multiple health benefits including improved blood glucose control, however, the consumption of fresh berries is limited by their short seasonal availability. Hydro-Thermodynamic (HTD) processing of blueberries allows the processing of whole berries including their skin and seeds into a beverage with the amount of anthocyanins comparable with fresh berries. The objective of the study is to investigate the effect of HTD-processed blueberries on postprandial glycaemia and antioxidant activity.


Eligibility criteria: Inclusion Criteria:

* Healthy adults
* Body mass index (BMI) within normal range (18.5-24.9 kg/m2 for adults)

Exclusion Criteria:

* Chronic metabolic diseases or inflammatory conditions
* Smokers
* A medication that influences glucose control or gastrointestinal function
* Known allergies
* Intellectual disabilities

Primary outcomes:
measure: Blood glucose
timeFrame: 0-120 min
Secondary outcomes:
measure: Postprandial antioxidant activity in blood
timeFrame: 0-120 min
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Mount Saint Vincent University
state: Nova Scotia
Study officials:
affiliation: Mount Saint Vincent University
name: Bohdan Luhovyy, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06157762: Open Technique Erector Spinae Plane Block in Spinal Surgery
Official title: Comparison of the Effectiveness of Preoperative Ultrasound-Guided Erector Spine Plane Block and Erector Spine Plane Block Performed by the Intraoperative Surgeon in Postoperative Analgesia in Patients Undergoing Lumbar Disc Herniation Surgery
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Postoperative Pain
Erector Spinae Plane Block in Spinal Surgery
Keywords: Pain
postoperative analgesia
Erector spinae plane block
Spinal surgery
Open Technique
Lead sponsor: Kahramanmaras Sutcu Imam University
Sponsor class: OTHER
First posted: 2023-12-06
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Erector spinae plane (ESP) block is an interfacial plane block with visceral and somatic analgesic activity at paraspinal muscles.ESPB has been successfully applied as a part of multimodal analgesia in treating postoperative pain in spinal surgery. However, it may be difficult or impossible to perform lumbar ESPB in obese patients or cases of increased lumbar lordosis. This study aims to investigate the effectiveness of ESPB applied by the intraoperative surgeon.


Eligibility criteria: Inclusion Criteria:

* ASA I-III patients
* Agreed to participate in the study

Exclusion Criteria:

* Patients with infection at the injection site
* Coagulopathy Allergy to amide-type local anesthetics
* History of peripheral neuropathy
* Hepatic and/or renal failure
* Refusing the procedure
* Patients with heart disease
* Patients who have previously undergone surgery from the same area

Primary outcomes:
measure: opioid consumption
timeFrame: up to 24 hour
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: